EUVIMEDEUVIMED entdecken
Open Access

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre‐ and post‐ponatinib era

Fadi G Haddad iD, Koji Sasaki iD, Aram Bidikian iD, Ghayas C Issa iD, Tapan Kadia iD, Nitin Jain iD, Yesid Alvarado, Nicholas J Short iD, Naveen Pemmaraju iD, Sanam Loghavi iD, Keyur P Patel, Rashmi Kanagal-Shamanna iD und 4 weitere

American Journal of Hematology · 2023

DOI: 10.1002/ajh.27037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Fadi G Haddad und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Pyridazines. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with chronic myeloid leukemia (CML) and T315I mutation generally have a poor prognosis. Their outcome in the post‐ponatinib era remains unclear. We reviewed patients with CML in chronic (CP) or accelerated phase (AP) who developed a T315I mutation between March 15, 2004, and July 26, 2022. Patients were divided into CP, AP, or blastic phase (BP) at the time of mutation detection. Overall survival (OS) was defined from the time of mutation detection to the date of death or last follow‐up. We identified a total of 107 patients: 54 (51%) in CP, 14 (13%) in AP, and 39 (36%) in BP. One hundred and two patients received subsequent therapy after the T315I mutation was detected. At a median follow‐up of 75 months (95% CI, 41–110), the median OS was 49 months (95% CI, 26–73) and the 5‐year OS rate was 44%. Patients who were in CML‐CP at the time of mutation detection had better survival compared with those in AP or BP, with a median OS of 132, 31, and 6 months, and 5‐year OS rates of 70%, 37%, and 10%, respectively ( p < .001). Patients with CML‐CP treated with ponatinib and/or asciminib had a 5‐year OS of 77% compared with 50% in those who received other treatments (chemotherapy, second‐generation tyrosine kinase inhibitors, homoharringtonine, and investigational drugs) ( p = .14). In summary, patients with CML‐CP at the time of T315I mutation detection may have a relatively indolent disease course with a long‐term OS of 70%. Treatment with third‐generation tyrosine kinase inhibitors seemed to improve survival in patients with CML‐CP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositivePyridazinesHumansDrug Resistance, NeoplasmFusion Proteins, bcr-ablImidazolesMutationProtein Kinase Inhibitors

Substanzen

Fusion Proteins, bcr-ablImidazolesponatinibProtein Kinase InhibitorsPyridazines

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Fadi G Haddad, Koji Sasaki, Aram Bidikian, Ghayas C Issa, Tapan Kadia, Nitin Jain, Nicholas J Short, Naveen Pemmaraju, Sanam Loghavi, Rashmi Kanagal-Shamanna, Musa Yilmaz, Elias Jabbour, Hagop Kantarjian

Förderung

  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Haddad, F. G., Sasaki, K., Bidikian, A., Issa, G. C., Kadia, T., Jain, N., Alvarado, Y., Short, N. J., Pemmaraju, N., Loghavi, S., Patel, K. P., Kanagal-Shamanna, R., Yilmaz, M., Masarova, L., Jabbour, E., & Kantarjian, H. (2023). Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre‐ and post‐ponatinib era. American Journal of Hematology. https://doi.org/10.1002/ajh.27037

Vancouver

Haddad FG, Sasaki K, Bidikian A, Issa GC, Kadia T, Jain N, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre‐ and post‐ponatinib era. American Journal of Hematology. 2023. doi:10.1002/ajh.27037

BibTeX
@article{Haddad2023,
  author = {Haddad, Fadi G and Sasaki, Koji and Bidikian, Aram and Issa, Ghayas C and Kadia, Tapan and Jain, Nitin and Alvarado, Yesid and Short, Nicholas J and Pemmaraju, Naveen and Loghavi, Sanam and Patel, Keyur P and Kanagal-Shamanna, Rashmi and Yilmaz, Musa and Masarova, Lucia and Jabbour, Elias and Kantarjian, Hagop},
  title = {Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre‐ and post‐ponatinib era},
  journal = {American Journal of Hematology},
  year = {2023},
  doi = {10.1002/ajh.27037}
}
Kostenlos starten →